Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICONIC: Neoadjuvant Envafolimab + Capox in MSS Colon Cancer
NCT05914389Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in colon cancer, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Aug 2023; status: recruiting.
02
Drugs
envafolimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT05914389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05914389.